Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts – Xconomy
Xconomy |
Bio Roundup: Lung Cancer Showdown, Gene Therapy Deals, IPO Busts
Xconomy Elsewhere this week, Novartis bet heavily on gene therapy while GlaxoSmithKline asked out, the Theranos saga rolled on, and a few biotechs to go public since 2015 crashed and burned. Let's round it all up. CANCER HEADLINES. —This year's American … |
